Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

24,817 signal articles · 258 in last 24h · 118,276 total before filter · latest 1h ago
258last 24h
1567last 7d
250● bullish (7d)
161● bearish (7d)
205publishers
AllMacro304Earnings632M&A97Regulatory28Product14Analyst23
✕ clear all filtersticker: NVDASentiment:bullishneutralbearish✓ showing all (incl. clickbait)
The Real Case for Buying Johnson & Johnson (JNJ) Before July 15
24/7 Wall St.36d agobullish
The Real Case for Buying Johnson & Johnson (JNJ) Before July 15

Johnson & Johnson (NYSE:JNJ) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setup leaves little to debate. The stock has already told you what it thinks of the fundamentals, rising nearly 25% year to date and nearly 66% over the past year. Yet the ... The Real Case for Buying Johnson & Johnson (JNJ) Before July 15

Intuitive Surgical Has +35% Upside: A Compelling Buy Story Before July 16
24/7 Wall St.36d agobullish
Intuitive Surgical Has +35% Upside: A Compelling Buy Story Before July 16

Intuitive Surgical (NASDAQ:ISRG) looks compelling ahead of its July 16 earnings report, and the setup rarely gets this clean for a category leader trading well below fair value. Shares sit at $413.58, down 26.71% YTD, while the 247 base-case target of $559.79 implies 35.35% upside. Wall Street sits higher still at $563.35, with 22 buy ... Intuitive Surgical Has +35% Upside: A Compelling Buy Story Before July 16

AI Chips Today - AI Advancements Revolutionize Drug Discovery and Cancer Treatment
Simply Wall St.36d agoneutral
AI Chips Today - AI Advancements Revolutionize Drug Discovery and Cancer Treatment

Recent developments in the AI chip sector include a notable collaboration between VERAXA Biotech and Ardigen. This partnership focuses on integrating artificial intelligence into drug discovery processes to enhance VERAXA's BiTAC pipeline, targeting cancer treatments. The AI will aid in selecting synergistic cancer target pairs, potentially improving therapeutic outcomes by reducing toxicity and systemic effects. This initiative highlights the growing role of AI chips in revolutionizing...

TSMC posts record revenue in second quarter on AI demand
Reuters Videos36d agoneutralVIDEO
TSMC posts record revenue in second quarter on AI demand

<body><p>STORY: TSMC reported record high second-quarter revenue on Monday.&nbsp;</p><p>The world’s largest contract chipmaker posted that Q2 revenue rose 36% from a year earlier on surging interest in AI applications.&nbsp;</p><p>Reuters calculated TSMC’s earnings came in at just over $39.6 billion - slightly above forecasts.&nbsp;</p><p>TSMC is a major supplier to companies including Nvidia and Apple.&nbsp;</p><p>For June alone, TSMC reported revenue rose almost 68% year-on-year to $13.8 billion - up 6% from the previous month.</p><p>TSMC, which is Asia's most valuable publicly listed company, didn't provide any details or forward guidance in its brief revenue statement.</p><p>It is scheduled to due to report second-quarter earnings on Thursday.</p><p>It's also due to update its outlook and plans for the current quarter and the rest of the year.</p><p>The company's shares have risen 57% so far this year, in line with the broader market.</p></body>